TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07197554: A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Sponsor: SEED Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 171 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07197554 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07197554 Rescue Dossier →